We thank Dr McKenna (and colleagues) for his interest in our editorial, and respect his long record of research into schizophrenia. His point about the authors of influential national clinical guidelines such as NICE, the British Association for Psychopharmacology (BAP) and the Scottish Intercollegiate Guidelines Network (SIGN) needing to take negative evidence into account is well made, and analogous to the AllTrials movement in pharmacotherapeutics. Schizophrenia is such a common and potentially devastating illness that it is incumbent on mental health professionals such as psychologists and psychiatrists to work together to deliver best-evidenced treatments.